| |
| |
|
| Insider
Information: |
Seidenberg Beth C |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
10 |
|
| Direct
Shares |
320,491 |
|
|
Indirect Shares
|
23,082,719 |
|
|
| Direct
Value |
$5,489,572 |
|
|
|
Indirect Value
|
$53,089,208 |
|
|
| Total
Shares |
23,403,210 |
|
|
| Total
Value |
$58,578,780 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
3
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
0.0
|
| Percentage
Gain/Loss : |
 -69.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
Sr VP, Dev & Chief Med... |
2004-12-31 |
15,343 |
2004-01-14 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2006-05-03 |
0 |
2006-05-03 |
3,000 |
Premium* |
|
|
Tesaro, Inc. |
TSRO |
Director |
2019-01-22 |
0 |
2019-01-22 |
0 |
Premium* |
|
|
Epizyme, Inc. |
EPZM |
Director |
2019-06-30 |
8,481 |
2019-06-30 |
4,115,555 |
Premium* |
|
|
Atara Biotherapeutics, Inc. |
ATRA |
|
2023-05-31 |
115,689 |
2023-05-31 |
1,877,044 |
Premium* |
|
|
Armo Biosciences Inc |
ARMO |
Director |
2018-01-30 |
0 |
2018-06-22 |
0 |
Premium* |
|
|
Progyny, Inc. |
PGNY |
Director |
2023-06-23 |
36,210 |
2023-06-23 |
5,302,521 |
Premium* |
|
|
Vera Therapeutics, Inc. |
VERA |
Director |
2021-05-18 |
0 |
2023-03-28 |
1,946,995 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Director, 10% Owner |
2023-05-09 |
60,000 |
2023-05-09 |
9,790,729 |
Premium* |
|
|
Sagimet Biosciences Inc. |
SGMT |
Director |
2023-07-18 |
84,768 |
2023-07-18 |
46,875 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
129 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SLRN |
Acelyrin, Inc. |
Director |
– • • |
2023-05-09 |
4 |
B |
$18.00 |
$1,080,000 |
D/D |
60,000 |
60,000 |
3.92 |
% |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • • |
2023-05-09 |
4 |
B |
$18.00 |
$22,500,000 |
I/I |
1,250,000 |
9,790,729 |
2.25 |
% |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • • |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
8,540,729 |
8,540,729 |
0 |
- |
|
| AMGN |
Amgen Inc |
Sr VP, Dev & Chief Medical Ofc |
• – – |
2004-01-14 |
4 |
D |
$64.05 |
$119,005 |
D/D |
(1,858) |
26,335 |
|
- |
|
| AMGN |
Amgen Inc |
Sr VP, Dev & Chief Medical Ofc |
• – – |
2004-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,377) |
15,343 |
|
- |
|
| AMGN |
Amgen Inc |
Sr VP, Dev & Chief Medical Ofc |
• – – |
2004-12-31 |
4 |
D |
$64.15 |
$392,662 |
D/D |
(6,121) |
20,720 |
|
- |
|
| ARMO |
Armo Biosciences Inc |
Director |
– • • |
2018-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
4,266,683 |
4,266,683 |
0 |
- |
|
| ARMO |
Armo Biosciences Inc |
Director |
– • – |
2018-06-22 |
4 |
D |
$50.00 |
$213,334,150 |
I/I |
(4,266,683) |
0 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • • |
2014-10-21 |
4 |
A |
$0.00 |
$0 |
I/I |
1,907,420 |
77,621 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • • |
2015-05-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(266,022) |
71,822 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • • |
2015-05-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(300,000) |
63,122 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2015-09-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(343,518) |
4,716 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2015-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
48,628 |
197 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2015-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,693 |
3,693 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2015-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,996 |
6,689 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2015-12-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,716) |
4,716 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
8,689 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
13,689 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
15,189 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
19,189 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,189 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
|
• • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
38,189 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
|
• • – |
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
58,689 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
115,689 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
– • – |
2006-05-03 |
4 |
B |
$15.21 |
$46,030 |
I/I |
3,000 |
3,000 |
2.1 |
- |
|
129 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
